EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Prognostic Factors of Castration‐Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot‐Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort ( MSUG94 )

Takeshi Sasaki iD, Atsushi Igarashi, Shin Ebara, Tomoyuki Tatenuma iD, Yoshinori Ikehata, Akinori Nakayama iD, Makoto Kawase iD, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama iD und 7 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70370 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Takeshi Sasaki und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Castration-Resistant, Robotic Surgical Procedures, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To explore clinicopathological risk factors associated with the development of castration‐resistant prostate cancer (CRPC) in patients who underwent robot‐assisted radical prostatectomy (RARP).

Methods

This study was conducted in nine Japanese institutions between 2012 and 2021. Patients with clinically metastatic PCa, those who received neoadjuvant or adjuvant therapy, were excluded. Consequently, 2825 patients with PCa were analyzed. Persistent prostate‐specific antigen (PSA) was determined as a level ≥ 0.2 ng/mL at 1 month postoperatively and consistently in subsequent measurements.

Results

Median follow‐up was 42.0 months. Under follow‐up, 493 (17.4%) and 25 (0.8%) patients progressed to biochemical recurrence and CRPC, respectively. One hundred and ninety‐six patients received salvage radiation therapy, and 229 patients received salvage androgen deprivation therapy. Among the 25 patients with CRPC, the median time to CRPC was 31.8 months. Univariate analysis revealed that preoperative PSA level, biopsy grade group (GG) 5, percentage of positive cancer cores, GG5 in RARP specimens, pT3b, pN1, positive surgical margins, lymphovascular invasion (LVI), and persistent PSA levels were associated with CRPC development. Multivariate analysis revealed that biopsy GG5 (adjusted hazard ratio [aHR] 12.74, p < 0.001), LVI (aHR 3.90, p = 0.011), and persistent PSA levels (aHR 8.66, p < 0.001) were independently associated with CRPC development. Furthermore, using these three factors made it possible to stratify CRPC‐free survival among patients with PCa who received RARP and confirmed external validation.

Conclusions

The combination of biopsy GG5, LVI, and persistent PSA levels may stratify the risk of developing CRPC in patients with PCa undergoing RARP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic Neoplasms, Castration-ResistantRobotic Surgical ProceduresNeoplasm Recurrence, LocalHumansMaleRetrospective StudiesAgedJapanMiddle AgedProstate-Specific AntigenPrognosisRisk FactorsSalvage TherapyNeoplasm GradingMargins of ExcisionProstateDisease ProgressionEast Asian People

Stichwörter der Autor:innen

biopsy grade group 5castration‐resistant prostate cancerlymphovascular invasionpersistent PSA

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Department of Urology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
  • Department of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Urology, Yokohama City University, Yokohama, Kanagawa, Japan.
  • Department of Urology, University of Toyama, Toyama, Japan.
  • Department of Urology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.

ORCID-Profile: Takeshi Sasaki, Tomoyuki Tatenuma, Akinori Nakayama, Makoto Kawase, Kazuhide Makiyama

Zitieren

APA

Sasaki, T., Igarashi, A., Ebara, S., Tatenuma, T., Ikehata, Y., Nakayama, A., Kawase, M., Toide, M., Yoneda, T., Sakaguchi, K., Teishima, J., Makiyama, K., Kitamura, H., Saito, K., Koie, T., Koga, F., Urakami, S., Yamasaki, T., & Inoue, T. (2026). Prognostic Factors of Castration‐Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot‐Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort ( MSUG94 ). International Journal of Urology. https://doi.org/10.1111/iju.70370

Vancouver

Sasaki T, Igarashi A, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, et al. Prognostic Factors of Castration‐Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot‐Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort ( MSUG94 ). International Journal of Urology. 2026. doi:10.1111/iju.70370

BibTeX
@article{Sasaki2026,
  author = {Sasaki, Takeshi and Igarashi, Atsushi and Ebara, Shin and Tatenuma, Tomoyuki and Ikehata, Yoshinori and Nakayama, Akinori and Kawase, Makoto and Toide, Masahiro and Yoneda, Tatsuaki and Sakaguchi, Kazushige and Teishima, Jun and Makiyama, Kazuhide and Kitamura, Hiroshi and Saito, Kazutaka and Koie, Takuya and Koga, Fumitaka and Urakami, Shinji and Yamasaki, Toshinari and Inoue, Takahiro},
  title = {Prognostic Factors of Castration‐Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot‐Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort ( MSUG94 )},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70370}
}
Kostenlos starten →